An oncologist evaluates a 52-year-old woman during a routine follow-up visit. The patient … — USMLE Step 3

An oncologist evaluates a $52$ -year-old woman during a routine follow-up visit. The patient has HER2-amplified, estrogen receptor-negative early-stage breast cancer. Three months ago, she completed adjuvant therapy with doxorubicin and cyclophosphamide and was subsequently started on maintenance therapy with trastuzumab.

The patient reports feeling well with no shortness of breath, orthopnea, or lower extremity edema. She walks $3$ kilometers daily without difficulty. Vital signs are within normal limits. Physical examination reveals clear lungs bilaterally, no jugular venous distention, and no peripheral edema.

A summary of her echocardiogram reports is provided below:

Parameter	Baseline (Pre-Trastuzumab)	Current (Today)
Left Ventricular Ejection Fraction (LVEF)	$62\%$	$46\%$
Regional Wall Motion	Normal	Diffuse global hypokinesis
Right Ventricular Function	Normal	Normal
Valvular Assessment	Trace mitral regurgitation	Trace mitral regurgitation

Which of the following is the most appropriate next step in managing this patient's therapy?

Hold trastuzumab and repeat echocardiography in 4 weeksAnswer
B
Discontinue trastuzumab permanently and initiate carvedilol
C
Continue trastuzumab and initiate carvedilol
D
Admit the patient to the hospital for intravenous furosemide
E
Obtain cardiac magnetic resonance imaging

Answer

The most appropriate next step is to hold trastuzumab and repeat echocardiography in 4 weeks.

The correct answer involves holding trastuzumab and repeating the echocardiogram in 4 weeks. Trastuzumab is associated with Type II cardiotoxicity, which usually presents as an asymptomatic decline in Left Ventricular Ejection Fraction (LVEF). Standard oncology guidelines mandate holding trastuzumab if the LVEF drops by

\geq 16\%

from baseline, or if the LVEF falls below the institutional limits of normal (usually

< 50\%

) with a

\geq 10\%

absolute drop. This patient's LVEF dropped from

62\%

46\%

, which satisfies both criteria. Because this toxicity is generally reversible and non-dose-dependent, the drug is held temporarily rather than discontinued permanently, and cardiac function is reassessed in 4 weeks to determine if therapy can be safely resumed.

Step-by-Step Solution

Analyze the patient's clinical presentation and echocardiogram results.

The patient is completely asymptomatic, but her LVEF has decreased from

62\%

46\%

(an absolute drop of

16\%

) over three months of trastuzumab therapy.

Identifying the precise magnitude of the LVEF decline is required to accurately apply oncologic monitoring guidelines.

Apply the clinical guidelines for trastuzumab-induced cardiotoxicity.

Because the absolute LVEF decrease is

\geq 16\%

(and the total LVEF is below the normal limit of

50\%

), the drug must be temporarily held to prevent progression to symptomatic heart failure.

Continuing the medication when standard cessation thresholds are met is contraindicated and risks severe patient harm.

Determine the appropriate follow-up monitoring interval.

A repeat echocardiogram should be scheduled in 4 weeks to assess for myocardial recovery.

Because Type II cardiotoxicity is often transient and reversible, reassessment in 4 weeks allows time for recovery while preventing premature permanent discontinuation of a highly effective cancer therapy.

Key Concept

Management of Trastuzumab-Induced Cardiotoxicity

Question

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Topics

More questions from this topic